Fujirebio Diagnostics, Inc. is a world leader in the production of in vitro diagnostics and the gold standard manufacturer of cancer biomarker assays worldwide. Biomarkers available from Fujirebio Diagnostics include: CA125II™, CA19-9™, CA15-3®, ProGRP, NSE, SCC, S100, CA 242, CA72-4©, CYFRA21-1™, and HE4, the first FDA cleared biomarker in 25 years for ovarian cancer management. Now cleared in the US is ROMA™ (Risk of Malignancy Algorithm). ROMA™ combines CA125 + HE4 to compute likelihood of ovarian malignancy.

This article waslast modified on March 1, 2018.